Do you want to read an article? Please log in or register.
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
Macular Diseases
Related content
COMMENTED
Macular Diseases
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
★ 1
Recommended by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Sci Rep
Ebneter A, Michels S, Pruente C, Imesch P, Eilenberger F, Oesch S, Thomet-Hunziker IP, Hatz K
doi: 10.1038/s41598-020-76354-1
COMMENTED
Macular Diseases
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
doi: 10.1016/j.ophtha.2020.03.021.
RECOMMENDED
Macular Diseases
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.11.018.
COMMENTED
Macular Diseases
Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser versus Monthly Dosing for DME: TREX-DME 2 Year Outcomes
Am J Ophthalmol.
Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group
doi: 10.1016/j.ajo.
COMMENTED
Macular Diseases
Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Br J Ophthalmol
Jaggi D, Nagamany T, Ebneter A, Munk M, Wolf S, Zinkernagel M
doi: 10.1136/bjophthalmol-2020-316514
Macular Diseases
Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes
Eye (Lond).
Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.
doi: 10.1038/s41433-018-0114-3.
Macular Diseases
AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes
Retina.
Bahrami B, Hong T, Schlub TE, Chang AA
doi: 10.1097/IAE.
Macular Diseases
Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study
Ophthalmol Retina.
Garweg JG, Stefanickova J, Hoyng C, Schmelter T, Niesen T, Sowade O, Sivaprasad S, AQUA Investigators.
doi: 10.1016/j.oret.2019.03.012.
Macular Diseases
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success
Graefes Arch Clin Exp Ophthalmol.
Laiginhas R, Silva MI, Rosas V, Penas S, Fernandes VA, Rocha-Sousa A, Carneiro Â, Falcão-Reis F, Falcão MS
doi: 10.1007/s00417-017-3836-1.